Global Influenza Diagnostics Market Research and Forecast 2018-2023
Influenza is a contagious respiratory illness that the influenza virus causes leading to the infection of nose, throat, and sometimes the lungs. It can result into mild to severe illness and sometimes can lead to death. Three types of influenza virus affect people that includes: type A, type B, and type C. Influenza is spread via infectious respiratory secretions that is caused by the formation of aerosol due to direct contact with an infected person. The influenza can cause seasonal epidemics along with high levels of mortality and morbidity.
A number of factors are responsible for the overall growth of the global influenza diagnostics market. Increasing prevalence of influenza and related chronic disease along with the rising geriatric population base is one of the major factors for the growth of the market. However, increasing price of diagnostic kits and reagents hinder the growth of the market. Moreover, there is a huge opportunity of the global influenza diagnostic market in the near future due to enormous funding and investment, and support provided by the government for influenza diagnostics. For an instance, San Diego-based Cue Health was awarded up to $30 million by the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority. The funding was provided for enhancing the development and regulatory validation of over-the-counter and professional-use influenza and multiplex respiratory pathogen diagnostic cartridges for health monitoring system of the company.
The influenza diagnostics market can be segmented on the basis of, type, test type and end users. Based on the type, the influenza diagnostics market is bifurcated as type A flu, type B flu and type C flu. On the basis of test type, the market is diversified as rapid influenza diagnostic test, serological assay, nucleic acid sequence-based amplification test, loop-mediated isothermal amplification-based assay, simple amplification-based assay and other tests. Based on the end users, the influenza diagnostics market is sub-divided as hospitals, and research labs.
The global influenza diagnostics market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The North America is expected to hold a substantial share in the influenza diagnostics market owing to the factors such as initiatives taken by the government for controlling the disease rate. In addition, health awareness among population is another motivating factor in the region. Moreover, APAC is projected to be an emerging market for influenza diagnostics due to high burden of the influenza in the region.
Some of the key players operating in the global influenza diagnostics market are Abbott Laboratories Inc., Novartis AG, Roche Diagnostics, Sekisui Diagnostics, SA Scientific, Inc., and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For instance, Silaris Influenza A&B Test has been launched by the Sekisui Diagnostics in March 2018. This test utilizes polymerase chain reaction (PCR) testing platform specifically for point-of-care (POC) infectious disease diagnosis. In addition, Sekisui Diagnostics along with the Mesa Biotech in November 2017, collaborated strategically for exclusive product distribution rights in the US and Canada.
RESEARCH METHODOLOGY
The market study of influenza diagnostics market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as American College of Rheumatology, American Association for Clinical Chemistry (AACC), and American Autoimmune Related Diseases Association (AARDA), among others.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for drug manufacturers, healthcare provider, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global Influenza diagnostics market is segmented on the basis of regional outlook and following segments:
Global Influenza diagnostics Market Research and Analysis, By Type
Global Influenza diagnostics Market Research and Analysis, By Test Type
Global Influenza diagnostics Market Research and Analysis, By End Users
Global Influenza diagnostics Market Research and Analysis, By Region
THE REPORT COVERS:
Comprehensive research methodology of global influenza diagnostics
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global influenza diagnostics market.
Insights about market determinants which are stimulating the global influenza diagnostics market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
A number of factors are responsible for the overall growth of the global influenza diagnostics market. Increasing prevalence of influenza and related chronic disease along with the rising geriatric population base is one of the major factors for the growth of the market. However, increasing price of diagnostic kits and reagents hinder the growth of the market. Moreover, there is a huge opportunity of the global influenza diagnostic market in the near future due to enormous funding and investment, and support provided by the government for influenza diagnostics. For an instance, San Diego-based Cue Health was awarded up to $30 million by the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority. The funding was provided for enhancing the development and regulatory validation of over-the-counter and professional-use influenza and multiplex respiratory pathogen diagnostic cartridges for health monitoring system of the company.
The influenza diagnostics market can be segmented on the basis of, type, test type and end users. Based on the type, the influenza diagnostics market is bifurcated as type A flu, type B flu and type C flu. On the basis of test type, the market is diversified as rapid influenza diagnostic test, serological assay, nucleic acid sequence-based amplification test, loop-mediated isothermal amplification-based assay, simple amplification-based assay and other tests. Based on the end users, the influenza diagnostics market is sub-divided as hospitals, and research labs.
The global influenza diagnostics market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The North America is expected to hold a substantial share in the influenza diagnostics market owing to the factors such as initiatives taken by the government for controlling the disease rate. In addition, health awareness among population is another motivating factor in the region. Moreover, APAC is projected to be an emerging market for influenza diagnostics due to high burden of the influenza in the region.
Some of the key players operating in the global influenza diagnostics market are Abbott Laboratories Inc., Novartis AG, Roche Diagnostics, Sekisui Diagnostics, SA Scientific, Inc., and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For instance, Silaris Influenza A&B Test has been launched by the Sekisui Diagnostics in March 2018. This test utilizes polymerase chain reaction (PCR) testing platform specifically for point-of-care (POC) infectious disease diagnosis. In addition, Sekisui Diagnostics along with the Mesa Biotech in November 2017, collaborated strategically for exclusive product distribution rights in the US and Canada.
RESEARCH METHODOLOGY
The market study of influenza diagnostics market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as American College of Rheumatology, American Association for Clinical Chemistry (AACC), and American Autoimmune Related Diseases Association (AARDA), among others.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for drug manufacturers, healthcare provider, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global Influenza diagnostics market is segmented on the basis of regional outlook and following segments:
Global Influenza diagnostics Market Research and Analysis, By Type
Global Influenza diagnostics Market Research and Analysis, By Test Type
Global Influenza diagnostics Market Research and Analysis, By End Users
Global Influenza diagnostics Market Research and Analysis, By Region
THE REPORT COVERS:
Comprehensive research methodology of global influenza diagnostics
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global influenza diagnostics market.
Insights about market determinants which are stimulating the global influenza diagnostics market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
CHAPTER 1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. RULES & REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. JAPAN
2.3.1.5. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. HIGH NUMBER OF RESEARCH INSTITUTES WORKING ON INFLUENZA DIAGNOSTICS
3.1.2. INCREASING PREVALENCE OF INFLUENZA AND RELATED CHRONIC DISEASES
3.1.3. RISING GERIATRIC POPULATION BASE
3.1.4. INCREASING DEMAND FOR POINT-OF-CARE TESTING
3.2. RESTRAINTS
3.2.1. INCREASING PRICE OF DIAGNOSTIC KITS AND REAGENTS
3.2.2. STRINGENT GOVERNMENT FRAMEWORK
3.3. OPPORTUNITIES
3.3.1. ENORMOUS FUNDING AND INVESTMENT AND GOVERNMENT INITIATIVES FOR INFLUENZA DIAGNOSTICS
3.3.2. RISING DEMAND FROM EMERGING ECONOMIES
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU
4.1.1. TYPE A FLU
4.1.2. TYPE B FLU
4.1.3. TYPE C FLU
4.2. GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE
4.2.1. RAPID INFLUENZA DIAGNOSTIC TESTS (RIDT)
4.2.2. SEROLOGICAL ASSAY
4.2.3. NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) TESTS
4.2.4. LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS (LAMP)
4.2.5. SIMPLE AMPLIFICATION-BASED ASSAYS (SAMBA)
4.2.6. OTHERS
4.3. GLOBAL INFLUENZA DIAGNOSTICS BY END USERS
4.3.1. HOSPITALS & DIAGNOSTIC CENTERS
4.3.2. RESEARCH LABS
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY COMPANY ANALYSIS
5.2. KEY STRATEGY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. 3M
7.2. ABBOTT LABORATORIES
7.3. ANALYTIK JENA AG
7.4. ANTECH DIAGNOSTICS
7.5. ARBOR VITA CORPORATION
7.6. BECTON, DICKINSON AND COMPANY
7.7. BIOFIRE DIAGNOSTICS, LLC
7.8. BIOMÉRIEUX SA
7.9. CARDINAL HEALTH, INC
7.10. CEPHEID INC
7.11. CREATIVE DIAGNOSTICS
7.12. CUE HEALTH INC.
7.13. DENKA SEIKEN CO., LTD.
7.14. DIAGENODE DIAGNOSTICS
7.15. ENIGMA DIAGNOSTICS LIMITED
7.16. F. HOFFMANN-LA ROCHE AG
7.17. FOCUS DIAGNOSTICS INC.
7.18. GENMARK DIAGNOSTICS, INC.
7.19. GLAXOSMITHKLINE PLC
7.20. HARDY DIAGNOSTICS
7.21. IDEXX LABORATORIES, INC.
7.22. LABORATORY CORPORATION OF AMERICA HOLDINGS
7.23. LIFESIGN LLC
7.24. LUMINEX CORPORATION
7.25. MEDLINE INDUSTRIES, INC.
7.26. MERCK MILLIPORE
7.27. MERIDIAN BIOSCIENCE INC.
7.28. MESA BIOTECH, INC.
7.29. MESO SCALE DIAGNOSTICS, LLC
7.30. NOVARTIS INTERNATIONAL AG
7.31. ORASURE TECHNOLOGIES, INC.
7.32. OTSUKA PHARMACEUTICAL CO., LTD.,
7.33. OY MEDIX BIOCHEMICA AB
7.34. QIAGEN N.V
7.35. QUEST DIAGNOSTICS INCORPORATED
7.36. QUIDEL CORPORATION
7.37. SA SCIENTIFIC LTD.
7.38. SEKISUI DIAGNOSTICS, LLC
7.39. THERMO FISHER SCIENTIFIC INC.
7.40. VIROCLINICS BIOSCIENCES B.V.
7.41. ZOETIS, INC.
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. RULES & REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. JAPAN
2.3.1.5. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. HIGH NUMBER OF RESEARCH INSTITUTES WORKING ON INFLUENZA DIAGNOSTICS
3.1.2. INCREASING PREVALENCE OF INFLUENZA AND RELATED CHRONIC DISEASES
3.1.3. RISING GERIATRIC POPULATION BASE
3.1.4. INCREASING DEMAND FOR POINT-OF-CARE TESTING
3.2. RESTRAINTS
3.2.1. INCREASING PRICE OF DIAGNOSTIC KITS AND REAGENTS
3.2.2. STRINGENT GOVERNMENT FRAMEWORK
3.3. OPPORTUNITIES
3.3.1. ENORMOUS FUNDING AND INVESTMENT AND GOVERNMENT INITIATIVES FOR INFLUENZA DIAGNOSTICS
3.3.2. RISING DEMAND FROM EMERGING ECONOMIES
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU
4.1.1. TYPE A FLU
4.1.2. TYPE B FLU
4.1.3. TYPE C FLU
4.2. GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE
4.2.1. RAPID INFLUENZA DIAGNOSTIC TESTS (RIDT)
4.2.2. SEROLOGICAL ASSAY
4.2.3. NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) TESTS
4.2.4. LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS (LAMP)
4.2.5. SIMPLE AMPLIFICATION-BASED ASSAYS (SAMBA)
4.2.6. OTHERS
4.3. GLOBAL INFLUENZA DIAGNOSTICS BY END USERS
4.3.1. HOSPITALS & DIAGNOSTIC CENTERS
4.3.2. RESEARCH LABS
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY COMPANY ANALYSIS
5.2. KEY STRATEGY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. 3M
7.2. ABBOTT LABORATORIES
7.3. ANALYTIK JENA AG
7.4. ANTECH DIAGNOSTICS
7.5. ARBOR VITA CORPORATION
7.6. BECTON, DICKINSON AND COMPANY
7.7. BIOFIRE DIAGNOSTICS, LLC
7.8. BIOMÉRIEUX SA
7.9. CARDINAL HEALTH, INC
7.10. CEPHEID INC
7.11. CREATIVE DIAGNOSTICS
7.12. CUE HEALTH INC.
7.13. DENKA SEIKEN CO., LTD.
7.14. DIAGENODE DIAGNOSTICS
7.15. ENIGMA DIAGNOSTICS LIMITED
7.16. F. HOFFMANN-LA ROCHE AG
7.17. FOCUS DIAGNOSTICS INC.
7.18. GENMARK DIAGNOSTICS, INC.
7.19. GLAXOSMITHKLINE PLC
7.20. HARDY DIAGNOSTICS
7.21. IDEXX LABORATORIES, INC.
7.22. LABORATORY CORPORATION OF AMERICA HOLDINGS
7.23. LIFESIGN LLC
7.24. LUMINEX CORPORATION
7.25. MEDLINE INDUSTRIES, INC.
7.26. MERCK MILLIPORE
7.27. MERIDIAN BIOSCIENCE INC.
7.28. MESA BIOTECH, INC.
7.29. MESO SCALE DIAGNOSTICS, LLC
7.30. NOVARTIS INTERNATIONAL AG
7.31. ORASURE TECHNOLOGIES, INC.
7.32. OTSUKA PHARMACEUTICAL CO., LTD.,
7.33. OY MEDIX BIOCHEMICA AB
7.34. QIAGEN N.V
7.35. QUEST DIAGNOSTICS INCORPORATED
7.36. QUIDEL CORPORATION
7.37. SA SCIENTIFIC LTD.
7.38. SEKISUI DIAGNOSTICS, LLC
7.39. THERMO FISHER SCIENTIFIC INC.
7.40. VIROCLINICS BIOSCIENCES B.V.
7.41. ZOETIS, INC.
LIST OF TABLES
TABLE 1 GLOBAL INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL TYPE A FLU MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL TYPE B FLU MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL TYPE C FLU MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL RAPID INFLUENZA DIAGNOSTIC TESTS (RIDT) MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL SEROLOGICAL ASSAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) TESTS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 9 GLOBAL LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS (LAMP) MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 10 GLOBAL SIMPLE AMPLIFICATION-BASED ASSAYS (SAMBA) MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 11 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 12 GLOBAL INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 13 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 14 GLOBAL RESEARCH LABS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 15 NORTH AMERICAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 16 NORTH AMERICAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 17 NORTH AMERICAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2017-2023 ($ MILLION)
TABLE 18 NORTH AMERICAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 19 EUROPEAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 20 EUROPEAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 21 EUROPEAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2017-2023 ($ MILLION)
TABLE 22 EUROPEAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 23 APAC INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 24 APAC INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 25 APAC INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2017-2023 ($ MILLION)
TABLE 26 APAC INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 27 ROW INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 28 ROW INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2017-2023 ($ MILLION)
TABLE 29 ROW INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 1 GLOBAL INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL TYPE A FLU MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL TYPE B FLU MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL TYPE C FLU MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL RAPID INFLUENZA DIAGNOSTIC TESTS (RIDT) MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL SEROLOGICAL ASSAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) TESTS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 9 GLOBAL LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS (LAMP) MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 10 GLOBAL SIMPLE AMPLIFICATION-BASED ASSAYS (SAMBA) MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 11 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 12 GLOBAL INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 13 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 14 GLOBAL RESEARCH LABS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 15 NORTH AMERICAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 16 NORTH AMERICAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 17 NORTH AMERICAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2017-2023 ($ MILLION)
TABLE 18 NORTH AMERICAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 19 EUROPEAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 20 EUROPEAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 21 EUROPEAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2017-2023 ($ MILLION)
TABLE 22 EUROPEAN INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 23 APAC INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 24 APAC INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 25 APAC INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2017-2023 ($ MILLION)
TABLE 26 APAC INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 27 ROW INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 28 ROW INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2017-2023 ($ MILLION)
TABLE 29 ROW INFLUENZA DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE BY TYPE, 2017 VS 2023 (%)
FIGURE 2 GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE BY TEST TYPE, 2017 VS 2023 (%)
FIGURE 3 GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE BY END USERS, 2017 VS 2023 (%)
FIGURE 4 US INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 5 CANADA INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 UK INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 FRANCE INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 GERMANY INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 ITALY INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 ROE INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 INDIA INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 13 CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 14 JAPAN INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 15 ROAPAC INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 16 REST OF THE WORLD INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. 3M
2. ABBOTT LABORATORIES
3. ANALYTIK JENA AG
4. ANTECH DIAGNOSTICS
5. ARBOR VITA CORPORATION
6. BECTON, DICKINSON AND COMPANY
7. BIOFIRE DIAGNOSTICS, LLC
8. BIOMÉRIEUX SA
9. CARDINAL HEALTH, INC
10. CEPHEID INC
11. CREATIVE DIAGNOSTICS
12. CUE HEALTH INC.
13. DENKA SEIKEN CO., LTD.
14. DIAGENODE DIAGNOSTICS
15. ENIGMA DIAGNOSTICS LIMITED
16. F. HOFFMANN-LA ROCHE AG
17. FOCUS DIAGNOSTICS INC.
18. GENMARK DIAGNOSTICS, INC.
19. GLAXOSMITHKLINE PLC
20. HARDY DIAGNOSTICS
21. IDEXX LABORATORIES, INC.
22. LABORATORY CORPORATION OF AMERICA HOLDINGS
23. LIFESIGN LLC
24. LUMINEX CORPORATION
25. MEDLINE INDUSTRIES, INC.
26. MERCK MILLIPORE
27. MERIDIAN BIOSCIENCE INC.
28. MESA BIOTECH, INC.
29. MESO SCALE DIAGNOSTICS, LLC
30. NOVARTIS INTERNATIONAL AG
31. ORASURE TECHNOLOGIES, INC.
32. OTSUKA PHARMACEUTICAL CO., LTD.,
33. OY MEDIX BIOCHEMICA AB
34. QIAGEN N.V
35. QUEST DIAGNOSTICS INCORPORATED
36. QUIDEL CORPORATION
37. SA SCIENTIFIC LTD.
38. SEKISUI DIAGNOSTICS, LLC
39. THERMO FISHER SCIENTIFIC INC.
40. VIROCLINICS BIOSCIENCES B.V.
41. ZOETIS, INC.
FIGURE 1 GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE BY TYPE, 2017 VS 2023 (%)
FIGURE 2 GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE BY TEST TYPE, 2017 VS 2023 (%)
FIGURE 3 GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE BY END USERS, 2017 VS 2023 (%)
FIGURE 4 US INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 5 CANADA INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 UK INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 FRANCE INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 GERMANY INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 ITALY INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 ROE INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 INDIA INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 13 CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 14 JAPAN INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 15 ROAPAC INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 16 REST OF THE WORLD INFLUENZA DIAGNOSTICS MARKET SIZE, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. 3M
2. ABBOTT LABORATORIES
3. ANALYTIK JENA AG
4. ANTECH DIAGNOSTICS
5. ARBOR VITA CORPORATION
6. BECTON, DICKINSON AND COMPANY
7. BIOFIRE DIAGNOSTICS, LLC
8. BIOMÉRIEUX SA
9. CARDINAL HEALTH, INC
10. CEPHEID INC
11. CREATIVE DIAGNOSTICS
12. CUE HEALTH INC.
13. DENKA SEIKEN CO., LTD.
14. DIAGENODE DIAGNOSTICS
15. ENIGMA DIAGNOSTICS LIMITED
16. F. HOFFMANN-LA ROCHE AG
17. FOCUS DIAGNOSTICS INC.
18. GENMARK DIAGNOSTICS, INC.
19. GLAXOSMITHKLINE PLC
20. HARDY DIAGNOSTICS
21. IDEXX LABORATORIES, INC.
22. LABORATORY CORPORATION OF AMERICA HOLDINGS
23. LIFESIGN LLC
24. LUMINEX CORPORATION
25. MEDLINE INDUSTRIES, INC.
26. MERCK MILLIPORE
27. MERIDIAN BIOSCIENCE INC.
28. MESA BIOTECH, INC.
29. MESO SCALE DIAGNOSTICS, LLC
30. NOVARTIS INTERNATIONAL AG
31. ORASURE TECHNOLOGIES, INC.
32. OTSUKA PHARMACEUTICAL CO., LTD.,
33. OY MEDIX BIOCHEMICA AB
34. QIAGEN N.V
35. QUEST DIAGNOSTICS INCORPORATED
36. QUIDEL CORPORATION
37. SA SCIENTIFIC LTD.
38. SEKISUI DIAGNOSTICS, LLC
39. THERMO FISHER SCIENTIFIC INC.
40. VIROCLINICS BIOSCIENCES B.V.
41. ZOETIS, INC.
